Latest in News & Research

Launch Alert: FDA Approves Emrosi for Inflammatory Lesions of Rosacea

The approval marks the first oral minocycline formulation for the papules and pustules characteristic of the condition

By Dermsquared Editorial Team | | November 07, 2024

Risk for Psoriasis Increased With Immune Checkpoint Inhibitor Use in Cancer

ICI users have about a twofold increase in risk for developing psoriasis, with findings consistent across all follow-up intervals

By Dermsquared Editorial Team | | November 06, 2024

Pain Prevalent Among Mohs Surgeons, Reported by 88.7 Percent

Male surgeons less often complain of upper back pain, but more often report lower back pain than female surgeons

By Dermsquared Editorial Team | | November 06, 2024

New Set of Risk Factors Can Boost Detection of Suspicious Skin Lesions

C4C risk score achieved sensitivity of 80.46 ± 2.50 percent and specificity of 62.09 ± 1.90 percent, outperforming other models

By Elana Gotkine (HealthDay News) | | November 04, 2024

First Cases of Sexually Transmitted Ringworm Reported in the U.S.

All five known cases involved men who have sex with men; the rashes cleared up with antifungal treatments

By Physician’s Briefing Staff (HealthDay News) | | October 31, 2024

Using Filtering Function Before Skin Biopsy Can Reduce Benign-to-Malignant Ratio

Health care system in Denmark employing filtering function before biopsy achieved low benign-to-malignant ratio over 15 years, but at high cost
By Dermsquared Editorial Team | | October 30, 2024

Potential Genetic Link ID'd Between Thyroid Disease, Alopecia Areata

Significant genetic predictions of alopecia seen with hypothyroidism, Hashimoto thyroiditis, and subacute thyroiditis
By Elana Gotkine (HealthDay News) | | October 30, 2024

Total, Facial Vitiligo Area Scoring Indices Effectively Differentiate Vitiligo Patients

Improvements of 30 percent in T-VASI and 50 percent in F-VASI reflect meaningful repigmentation between baseline, week 24

By Dermsquared Editorial Team | | October 30, 2024

FDA Approves EBGLYSS for Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents

The IL-13 inhibitor offers a new first-line biologic treatment option for moderate-to-severe atopic dermatitis not well-controlled with topicals

By Dermsquared Editorial Team | | October 21, 2024

Remote Cutaneous Confocal Microscopy Has Good Diagnostic Accuracy for Skin Malignancy

Sensitivity of remote CCM was 89 percent, specificity was 64 percent for detection of malignancy

By Dermsquared Editorial Team | | October 16, 2024

Superior Drug Survival Seen for Dupilumab in Pediatric Patients With AD

Risk for drug discontinuation higher due to ineffectiveness, adverse events for MTX, CsA versus dupilumab

By Dermsquared Editorial Team | | October 16, 2024

Relationship Suggested Between Hyperhidrosis, Sensitive Skin

Sensitive skin occurred on body sites that were and were not affected by hyperhidrosis

By Elana Gotkine (HealthDay News) | | October 15, 2024

Benzene Exposure Results From Benzoyl Peroxide Drug Product Use

Benzene concentrations detected in 111 over-the-counter BPO drug products that were tested, maintained at room temperature

By Elana Gotkine (HealthDay News) | | October 11, 2024

Risk for Second Melanoma Up for Those With First Melanoma Diagnosis

Melanoma less common among racial and ethnic minorities, but they still have increased rate of second primary melanoma

By Elana Gotkine (HealthDay News) | | October 09, 2024

Disease-Specific Survival Equal for Mohs, Wide Local Excision in Cutaneous Leiomyosarcoma

DSS similar with Mohs micrographic surgery, wide local excision treatment; findings persist in adjusted analysis

By Dermsquared Editorial Team | | October 09, 2024

Serum, Tissue Levels of CXCL9 Elevated in Nonsegmental Vitiligo

Serum and tissue levels of CXCL9 are reduced after 12 weeks of narrowband ultraviolet B phototherapy

By Dermsquared Editorial Team | | October 09, 2024

Welcome ADCS team to Dermsquared!

Welcome to our premium experience for ADCS clinicians and professionals

By Dermsquared Editorial Team | | October 08, 2024

Bimekizumab Safe, Efficacious Over Two Years for Hidradenitis Suppurativa

Clinically meaningful efficacy outcomes observed at one year maintained to two years of treatment

By Elana Gotkine (HealthDay News) | | October 07, 2024

Long-Term Efficacy for Lebrikizumab Seen in Moderate, Severe Eczema

Long-term efficacy seen for lebrikizumab every two weeks or every four weeks in moderate-to-severe atopic dermatitis

By Elana Gotkine (HealthDay News) | | October 04, 2024

Anti-CTAg Antibodies Identified in Stage I, II Melanoma

Specific antibodies against three tumor antigens identified as promising diagnostic biomarkers for early-stage melanomas

By Elana Gotkine (HealthDay News) | | October 02, 2024

Incidence of Epidermal Necrolysis 2.6 Cases Per Million Person-Years

Factors associated with in-hospital mortality include age, history of cancer, dementia, liver disease, EN severity

By Dermsquared Editorial Team | | October 02, 2024

AI Model Exhibits Diagnostic Bias Towards Fitzpatrick I to III Subgroup

VisualDX demonstrated significantly greater sensitivity for Fitzpatrick I to III subgroup than Fitzpatrick IV to VI and a processed image subgroup

By Dermsquared Editorial Team | | October 02, 2024

Home-Based Phototherapy as Effective as Office-Based for Psoriasis

For plaque or guttate psoriasis, home-based phototherapy noninferior to office-based phototherapy for PGA and DLQI

By Elana Gotkine (HealthDay News) | | September 30, 2024

24 of 1200

Headline from the Week of February 09 - 15, 2026

Second Annual National Cancer Database Report Presented for 2022

By Elana Gotkine (HealthDay News) | | February 11, 2026

Presurgical Pembrolizumab Beneficial for Desmoplastic Melanoma

By Elana Gotkine (HealthDay News) | | February 11, 2026